haemoctin sdh 250 for injection 250 iuvial
grifols asia pacific pte. ltd. - human blood coagulation factor viii - injection, powder, for solution - 250 iu/vial - human blood coagulation factor viii 250 iu/vial
haemoctin sdh 500 for injection 500 iuvial
grifols asia pacific pte. ltd. - human coagulation factor viii - injection, powder, lyophilized, for solution - 500iu/vial - human coagulation factor viii 500iu/vial
recombinate 250 iu powder and solvent for solution for injection
baxter healthcare limited - octocog alfa 25 iu/ml - powder and solvent for solution for injection
recombinate 500iu powder and solvent for solution for injection
baxter healthcare limited - octocog alfa 500 iu - powder and solvent for solution for injection
recombinate 1000iu powder and solvent for solution for injection
baxter healthcare limited - octocog alfa 1000 iu - powder and solvent for solution for injection
refacto af
pfizer europe ma eeig - moroctocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency). refacto af is appropriate for use in adults and children of all ages, including newborns. refacto af does not contain von-willebrand factor, and hence is not indicated in von-willebrand's disease.,
haemoctin sdh 1000 for injection 1000 iuvial
grifols asia pacific pte. ltd. - human coagulation factor viii - injection, powder, lyophilized, for solution - human coagulation factor viii 1000 iu/vial
kogenate bayer
bayer ag - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency).this preparation does not contain von willebrand factor and is therefore not indicated in von willebrand's disease.
fanhdi 25 iuml (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 250 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a .fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
fanhdi 50 iuml (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 500 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.